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Summary 
It is becoming increasingly clear that defects in RNA metabolism can lead to disease. 
Spinal Muscular Atrophy (SMA), a leading genetic cause of infant mortality, results from 
insufficient amounts of survival motor neuron (SMN) protein. SMN is required for the 
biogenesis of snRNPs: essential components of the spliceosome. Splicing abnormalities 
have been detected in models of SMA but it is unclear how lowered SMN affects the 
fidelity of pre-mRNA splicing. We have examined the dynamics of mature snRNPs in 
cells depleted of SMN and demonstrated that SMN depletion increases the mobility of 
mature snRNPs within the nucleus. To dissect the molecular mechanism by which SMN 
deficiency affects intra-nuclear snRNP mobility, we employed a panel of inhibitors of 
different stages of pre-mRNA processing. This in vivo modeling demonstrates that 
snRNP mobility is altered directly as a result of impaired snRNP maturation. Current 
models of nuclear dynamics predict that sub-nuclear structures, including the 
spliceosome, form by self-organization mediated by stochastic interactions between 
their molecular components. Thus, alteration of the intra-nuclear mobility of snRNPs 
provides a molecular mechanism for splicing defects in SMA. 
 
 
 
 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
A
cc
ep
te
d 
m
an
us
cr
ip
t
 3
Introduction 
The spliceosome is a multi-component molecular machine responsible for the catalysis 
of pre-mRNA splicing. The organization of the spliceosome within mammalian cell 
nuclei is a complex and dynamic process. Splicing snRNPs (small nuclear 
ribonuceoproteins) form the core of the spliceosome. The major spliceosome comprises 
U1, U2, U5, U4/U6 snRNPs, while in the minor spliceosome U1 and U2 are replaced by 
U11 and U12 (Tarn and Steitz, 1996). Each snRNP comprises a core of uridine-rich small 
nuclear RNA (U1, U2, U5, U4/U6, U11, U12) complexed with the seven Sm proteins (Sm 
B/B’, D1, D2, D3, E, F and G) and other proteins specific to each snRNP (reviewed in Will 
and Luhrmann, 2001). Splicing snRNPs have a complex pattern of localization within 
the cell, reflecting their complex biogenesis. With the exception of U6, whose biogenesis 
is thought to be entirely nuclear (reviewed in Patel and Bellini, 2008), snRNAs are 
transcribed by RNA PolII in the nucleus then exported to the cytoplasm where the Sm 
proteins are assembled into a ring structure around the snRNA (Kambach et al., 1999; 
Stark et al., 2001). This process is co-ordinated and controlled by the survival of motor 
neurons (SMN) complex (reviewed in Battle et al., 2006; Chari et al., 2009). Decreased 
amounts of SMN protein lead to the inherited neurodegenerative condition, Spinal 
Muscular Atrophy (SMA). Following the assembly of the Sm core, the 5’ cap of the U 
snRNA becomes hypermethylated and the 3’ end is trimmed before the partially mature 
snRNP can be reimported into the nucleus. On entry into the nucleus, snRNPs 
accumulate in Cajal bodies (Carvalho et al., 1999; Sleeman and Lamond, 1999) where 
their maturation continues (reviewed in Cioce and Lamond, 2005). In many, but not all, 
cells Cajal bodies co-localize with their twin structures, gems (Gemini of Cajal bodies) 
that contain the SMN protein (Liu and Dreyfuss, 1996). Cajal bodies are also implicated 
in the recycling of snRNPs after spliceosome disassembly (Schaffert et al., 2004; 
Sleeman, 2007; Stanek et al., 2008; Stanek et al., 2003). Mature splicing snRNPs localize 
to nuclear speckles (also termed interchromatin granules clusters (IGCs)), which are 
thought to provide a reservoir of mature snRNPs for recruitment to active spliceosomes 
when needed (reviewed in Spector and Lamond, 2011). Various strategies for modelling 
the kinetic behaviour of snRNPs and other pre-mRNA splicing factors suggest that 
splicing factors are in constant dynamic exchange in and out of speckles and that the 
speckles form by self-organization dependant on the dynamic interactions of their 
components (reviewed in Iborra and Cook, 2002; Misteli, 2001a, b, 2010). The active 
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spliceosome itself is also proposed to be a self-organizing structure formed as a result of 
stochastic interactions between individual protein and RNA components (reviewed in 
Rino and Carmo-Fonseca, 2009). Since the movement of splicing factors and other 
proteins within the nucleus occurs by anomalous diffusion with their movement slowed 
by transient binding to specific sites of biological importance (Kruhlak et al., 2000; 
Phair and Misteli, 2000; Rino et al., 2007), the intra-nuclear dynamics of snRNPs reflect 
the balance of their activity in spliceosomes and storage in speckles. 
 
The inherited neurodegenerative condition SMA, one of the leading genetic causes of 
infant mortality, is caused by lowered levels of the SMN protein with the degree of 
reduction of SMN showing some correlation with the severity of symptoms (Coovert et 
al., 1997; Lefebvre et al., 1997). Despite the well-defined role for SMN in early 
cytoplasmic stages of splicing snRNP assembly, the mechanism by which SMN reduction 
leads to symptoms of motor neuron loss and subsequent muscle degeneration is 
unknown. It is unclear whether motor neurons are particularly sensitive to defects in 
splicing snRNP maturation or whether SMN has an additional motor neuron-specific 
function. A comparison of mouse models of SMA exhibiting differing phenotypic 
severities revealed a correlation between the degree of impairment of snRNP assembly 
and the severity of symptoms (Gabanella et al., 2007). Cell type-specific and snRNP-
specific alterations in the repertoire of snRNAs have been detected in severe SMA mice 
and in HeLa cells showing 15% or less of normal SMN levels (Gabanella et al., 2007; 
Zhang et al., 2008). Widespread defects in splicing were also detected in severe SMA 
mice leading to the proposal that changes in the stochiometry of snRNPs may result in 
splicing abnormalities by affecting the efficiency, rate and fidelity of spliceosome 
assembly on different introns (Zhang et al., 2008) with important motor neuron-specific 
transcripts preferentially affected. Defects in splicing events mediated by both the 
minor and the major spliceosomes have been identified in cells from SMA patients with 
40-50% of normal SMN levels (Boulisfane et al., 2011; Fox-Walsh and Hertel, 2009; Wan 
et al., 2005) while SMN-deficient fission yeast also show splicing defects consistent with 
inefficient spliceosome formation (Campion et al., 2010). To date, however, no key 
neural transcripts affected by SMN-depletion in mammals have been identified and the 
molecular mechanism linking an altered snRNP repertoire to the varied and widespread 
splicing defects seen is not clear. We have examined the effect of SMN reduction on the 
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localization and dynamics of splicing snRNPs in a human neural cell line and in 
fibroblasts from an SMA patient. Our data reveal significant alterations in the rates of 
movement of snRNPs within the nuclei of SMN-depleted cells that provide a possible 
mechanistic link between defects in ribonucleoprotein assembly and defects in splicing. 
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Results 
1) SMN can be reduced effectively by RNAi in HeLa and SH-SY5Y cells. 
It is well established that lowered levels of SMN result in the loss of SMN from nuclear 
gems and defects in splicing snRNP maturation (Clelland et al., 2009; Girard et al., 2006; 
Gonsalvez et al., 2007; Lemm et al., 2006; Shpargel and Matera, 2005). In order to 
investigate the effect of decreased levels of SMN on the structure of splicing factor 
speckles and on the dynamics of mature splicing snRNPs, we identified siRNA 
sequences capable of reducing SMN levels in HeLa cells and in the neuroblastoma cell 
line SH-SY5Y. Transient transfection of HeLa cells with two independent siRNA 
duplexes to SMN (SMN 01 and SMN 05) led to a dramatic reduction in the number of 
SMN-positive nuclear gems after 24 hrs in comparison to cells transfected with non-
targeting duplexes or control duplexes targeting lamin A/C (Fig. 1A,B). Transfection of 
SH-SY5Y cells with siRNA duplexes to SMN resulted in a reduction to 48% of normal 
SMN protein levels after 24 hrs and 32% of normal after 48 hrs (Fig. 1 C,D) compared to 
transfection with non-targeting duplexes or control duplexes targeting PPIB. 
2) SMN reduction can be achieved using expression of shRNAs 
We have previously demonstrated that the neuroblastoma cell line, SH-SY5Y, has 
relatively low endogenous levels of SMN with a small over-expression of SMN able to 
increase the rate of accumulation of newly-assembled snRNPs in nuclear speckles 
(Clelland et al., 2009). This cell line is an ideal model in which to study the effect of SMN 
reduction on mature snRNPs because it is the level of SMN that limits the splicing 
snRNP assembly pathway in SH-SY5Y cells. In order to investigate the dynamics of 
mature snRNPs in SMN-depleted SH-SY5Y cells, it was essential to unequivocally 
identify living cells with lowered levels of SMN. To achieve this, we used the sequence 
identified above as capable of reducing SMN levels to generate plasmids to express 
small hairpin RNAs (shRNAs) from an H1 promoter with GFP expressed from a PGK 
promoter on the same plasmid (pSuperGFP, oligoengine). SH-SY5Y cells were 
transfected with these vectors and assayed for SMN expression after 24, 48 and 72 
hours by indirect immunofluorescence using antibodies to SMN. Transfected SH-SY5Y 
cells, identified by expression of GFP, showed reduced SMN levels after 48 hours of 
shRNA expression (Fig. 2A,B,C). This reduction was also evident at 72 hours. Expression 
of a control plasmid expressing shRNAs to target PPIB had no effect on SMN levels or 
distribution (Fig. 2D). Quantitation of the SMN fluorescence signal 48 hours after 
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transfection with plasmids targeting SMN reveals a reduction to an average of 46% of 
normal SMN levels in whole cells and to an average of 56% of normal SMN in nuclei (Fig. 
2E). These data demonstrate that shRNA expression can efficiently reduce SMN in SH-
SY5Y cells to levels comparable to those seen in cells from SMA patients, but that longer 
incubation is required in comparison to direct transfection of siRNA duplexes. 
Furthermore the loss of SMN appears to be more pronounced in the cytoplasm than in 
the nucleus. 
3) Reduction of SMN does not disrupt the structure of splicing speckles 
Depletion of SMN has been demonstrated to lead to inefficient snRNP assembly 
(reviewed in Pellizzoni, 2007) and to a delay in newly assembled snRNPs reaching 
splicing factor speckles (Girard et al 2006). However, the effect of SMN depletion on 
nuclear speckles containing mature splicing factors has not been examined in detail. 
Although the level of SMN available is the limiting factor in the rate of snRNP 
accumulation in speckles in SH-SY5Y neuroblastoma cells (Clelland et al., 2009), 
reduction of SMN levels using shRNA expression does not cause an appreciable defect in 
the localization of steady-state splicing factors in speckles (Fig. 3). The SR domain 
splicing factor SC-35 (A), core snRNP Sm proteins (B), the U1 snRNP-specific protein 
U1A (C) and snRNAs, detected using an antibody to their tri-methyl guanosine cap (D), 
all show normal localization in SH-SY5Y cells depleted of SMN for 48hrs (compare 
transfected cells, green on overlay, with control cells in the same panel). It is notable, 
however, that SH-SY5Y cells show accumulations of TMG-capped snRNAs in their 
cytoplasm (arrows in D), suggesting that snRNP assembly is less efficient in these cells 
than in HeLa cells where such accumulations are not seen (Carvalho et al., 1999; 
Sleeman et al., 2003). 
4) Mature snRNPs show alterations in their dynamics in cells depleted of SMN.  
Because the spliceosome is believed to assemble by self-organization, it is important to 
address the intra-nuclear dynamics of splicing factors in addition to their steady-state 
distribution.  In order to study the dynamics of splicing snRNPs in SMN-depleted cells, 
we first established cell lines constitutively expressing mCherry-tagged SmB. mCherry-
SmB is efficiently incorporated into snRNPs (Clelland 2009) and co-localizes with 
endogenous Sm proteins within the nucleus (Fig. 4A).  
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Two of these lines, mCherrySmBSHY03 and mCherrySmBSHY12, were used for FRAP 
analyses following transfection with a plasmid to reduce SMN levels or with control 
plasmids (targeting expression of PPIB or non-targeting). Transfected cells were 
identified by their expression of GFP.
 
Using a texas red filter set to visualize mCherry, 
nuclear speckles were bleached using a fixed laser pulse of
 
1 second at 532 nm and 
short adaptive time-lapse sequences taken
 
to determine the recovery kinetics (Fig. 
4B,C). Comparison of these kinetics in SMN-depleted cells versus control cells revealed 
a significant decrease in the half-time of recovery of mCherry-SmB-tagged snRNPs to 
splicing speckles in cells with lowered levels of SMN (Fig 4D). The mobile fraction of 
mCherry-SmB-tagged snRNPs, around 40%, was unaltered by depletion of SMN. The 
immobile fraction of mCherry-SmB is larger than that seen for many non-snRNP 
splicing factors, in agreement with previous data (Sleeman 2007, Rino et al, 2007, 
Huranova et al, 2010). The nature of this immobile fraction is not known, but it is 
unlikely to represent snRNPs actively involved in pre-mRNA splicing as splicing occurs 
co-transcriptionally and not within speckles. 
 
We have previously observed that the kinetics of exchange of photoactivatable GFP-
SmB-containing snRNPs in Cajal bodies are best modeled using a two phase, rather than 
a one phase, exponential decay curve (Sleeman, 2007) with a slow moving and a rapidly 
moving pool of signal present. It is difficult to determine the nature of the rapidly 
exchanging pool. It may represent free SmB or low-affinity binding of a sub-set of 
assembled snRNPs. Alternatively, it may suggest that the FRAP recovery is diffusion-
coupled (Sprague and McNally, 2005). Comparison of non-linear regression models 
using the extra sum-of-squares F test demonstrates that the recovery of mCherry-SmB 
to nuclear speckles also fits significantly better to a two-phase than to a one-phase 
recovery curve (Fig. 4E). It is possible that the faster-moving component (t1/2 ~0.5s) 
represents free mCherry-SmB. The core Sm proteins are added onto snRNAs in an early, 
cytoplasmic, stage of snRNP biogenesis with the Sm protein and tri-methylguanosine 
cap of the snRNA contributing to the nuclear import signal of the partially mature 
snRNP (Huber et al., 2002; Narayanan et al., 2004; Ospina et al., 2005). We would, 
therefore, not expect to find a significant amount of free mCherry-SmB in the nucleus. 
However, nuclear import of free Sm proteins has not been conclusively ruled out. In 
each of our experiments, both the t1/2 of this faster component, and the amount of the 
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signal recovering rapidly, remained constant while the t1/2 of the slower moving 
fraction decreased significantly (Fig. 4F). We can, therefore, be confident that the 
alterations in dynamics of mCherry-SmB observed represent alterations in the mobility 
of intact snRNPs, rather than an increase in any free mCherry-SmB present in the 
nucleus. Our analysis suggests that, although splicing speckle morphology is not grossly 
disrupted by the depletion of SMN, the dynamics of interaction of Sm-containing 
snRNPs with speckles are significantly altered. The increase in mobility of snRNPs 
within the nucleus is indicative of decreased affinity of binding to specific sites.  
5) Both the major spliceosomal U1 snRNP and the minor splicosomal 
U11/U12 snRNP have altered mobility in cells depleted of SMN. 
SmB is present in snRNPs from both the major (U1/U2) and minor (U11/U12) 
spliceosomes. Alterations in the repertoire of snRNPs have been implicated in the 
splicing defects seen in SMN-depleted HeLa cells and severe SMA mice with the 
suggestion that the levels of minor snRNPs are preferentially affected by SMN depletion. 
However, these changes were different in different tissues and it is unclear whether all 
snRNPs or predominantly the minor U11/U12 snRNPs are affected. To address this, we 
extended our FRAP analyses to look independently at the dynamics of the U1 snRNP 
and the U11/U12 snRNP. SH-SY5Y cell lines constitutively expressing the U1snRNP-
specific protein mCherry-U170K (Ellis et al., 2008, a gift from David Lleres and Angus 
Lamond, University of Dundee) were established and FRAP experiments performed as 
described above. A significant decrease in half-time of recovery of mCherry-U170K to 
speckles resulting from SMN depletion was also seen in these experiments (Fig. 5A, B). 
As with mCherry-SmB labeled snRNPs, the change only affected the slower moving 
fraction of the signal, with the relative amounts of slow and fast signal unaltered. This is 
indicative of increased mobility of mature, fully assembled U1 snRNPs. We next 
investigated the mobility of the U11/U12 snRNP-specific protein SNRNP35, which 
shows significant homology to U170K (Will et al., 1999, a gift from Prof. R. Lührmann, 
Max Plank Institute for Biophysical Chemistry). SH-SY5Y cell lines were established 
constitutively expressing mCherry-SNRNP35. The localization of mCherry-SNRNP35 
was clearly nuclear with a slight accumulation in nuclear speckles (Fig. 4C) as 
previously reported for the equivalent protein in Arabidopsis (Lorkovic et al, 2005). 
FRAP experiments again demonstrated a significant reduction in the half-time of 
recovery of the slower moving fraction (Fig. 4D,E). Interestingly, the reduction seen for 
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the U11/U12-specific SNRNP35 protein was more dramatic than that seen for the 
U1snRNP-specific U170K protein, suggesting that both the abundance and the mobility 
of the minor snRNPs are preferentially affected by SMN depletion. 
6) Increased snRNP mobility is seen in fibroblasts from a Spinal Muscular 
Atrophy Type 1 patient. 
To ascertain the relevance of changes in intra-nuclear snRNP mobility to SMA, we 
investigated the mobility of mCherry-U170K in fibroblasts from an SMA type1 patient 
and his unaffected mother (Coriell cell repository lines GM03813 and GM03814 
respectively). Again, no gross structural abnormalities of nuclear speckles were 
detected in the SMA patient fibroblasts (Fig. 6A,B). FRAP analyses of these fibroblasts 
expressing mCherry-U170K for 72 hours revealed a similar decrease in the half time of 
recovery of this protein to speckles as was observed in SH-SY5Y cells depleted of SMN 
experimentally (Fig. 5A,B). This clearly demonstrates that defects in splicing snRNP 
mobility are associated with lowered levels of SMN in patients as well as in our cell 
culture models of SMA. 
7) The alteration in splicing snRNP dynamics is a direct consequence of 
defective snRNP biogenesis in SMN-depleted cells. 
Splicing defects have been reported in several models of SMA including SMN-depleted 
cells, while early studies of SMN function also suggested that it may have an additional 
direct role in splicing (Pellizzoni et al., 1998). Since increased mobility of splicing 
factors can be caused by inhibition of transcription or splicing (Kruhlak et al., 2000; 
Phair and Misteli, 2000; Rino et al., 2007), it was important to determine whether the 
alteration of snRNP dynamics caused by SMN depletion occurs as a result of defects in 
splicing or is a potential mechanism for the defects. To address this, we made a detailed 
analysis of the kinetic changes seen in cells treated to inhibit different stages of mRNA 
production. Cell lines stably expressing mCherry-SmB were treated with 5,6-dichloro-1-
ß-D-ribobenzimidazole (DRB) to inhibit transcription, spliceostatin A (SSA) (Kaida et al., 
2007, a gift from M. Yoshida, RIKEN, Japan) to inhibit pre-mRNA splicing directly and 
leptomycin B (LMB) (Fornerod et al., 1997) to inhibit the export of nascent snRNAs and, 
hence, to indirectly inhibit snRNP assembly. In agreement with previous reports 
studying a number of different splicing factors (Rino et al., 2007), DRB treatment 
resulted in significantly faster kinetics of exchange of snRNPs within speckles, again 
affecting preferentially the slower moving fraction (Fig. 7). However, in contrast to our 
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results seen in SMN-depleted cells, DRB treatment also resulted in a significant increase 
in the mobile fraction of rapidly moving signal and in noticeably altered speckle 
morphology (Fig. 7). Direct inhibition of splicing with SSA resulted in alterations in 
speckle morphology indistinguishable from those produced by inhibition of 
transcription by DRB (Fig. 7). However, this was associated with an increase in the 
mobile fraction of the slower moving component but no significant alteration in either 
t1/2. We have previously reported that inhibition of snRNP assembly with LMB for 
three hours does not affect the interaction of transiently expressed PA-GFP-SmB-
tagged-snRNPs with speckles (Sleeman, 2007). This remains the case in cells stably 
expressing mCherry-SmB. However, treatment with LMB for 16 hours or more can 
successfully replicate the changes in dynamics seen in SMN-depleted cells (Fig. 7) with 
no discernable alterations to speckle morphology. This in-vitro modelling indicates that 
the changes in snRNP dynamics seen in SMN-depleted cells do not result from indirect 
or direct inhibition of pre-mRNA splicing, but are a direct consequence of inefficient 
splicing snRNP maturation (Fig. 8). 
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DISCUSSION 
SMN depletion does not alter splicing speckle morphology but leads to significant 
changes in splicing snRNP dynamics. 
The role of SMN in splicing snRNP biogenesis is well established. Despite evidence that 
SMN depletion has a profound effect on the formation of new snRNPs (reviewed in 
Chari et al., 2009), no obvious alteration in speckle morphology is seen in SMN-deficient 
cells using antibodies to snRNP proteins, snRNAs or non-snRNP splicing factors (Figs. 3 
and 6). Analysis of the exchange of snRNPs within splicing speckles, however, reveals a 
significant increase in the intra-nuclear mobility of mature snRNPs in SMN-depleted 
cells and in cells from an SMA patient. Increased mobility of snRNPs is indicative of their 
reduced interaction with binding sites within the nucleus. This observation emphasises 
the importance of examining the flux of factors, rather than just their steady state 
localization, when investigating dynamic nuclear compartments. 
Dynamics of both the major spliceosomal U1 snRNP and the minor spliceosomal 
U11/U12 snRNP are affected by SMN depletion 
While there are now a number of reports of splicing defects associated with lowered 
levels of SMN, including both changes to alternative splicing and inaccurate or defective 
splicing, the mechanism for these defects is unclear. Alterations in the repertoire of 
snRNPs have been noted in HeLa cells, MN1 cells and mouse models of SMA (Gabanella 
et al., 2007; Zhang et al., 2008) with the minor U11 and U12 snRNPs preferentially 
affected. However, splicing defects seen in mouse models (Baumer et al., 2009; Zhang et 
al., 2008) and higher rates of errors in splice site pairing seen in SMA patient fibroblasts 
(Fox-Walsh and Hertel, 2009) do not appear to preferentially affect transcripts spliced 
by the minor spliceosome. Other studies have not detected significant alterations in the 
amounts of steady-state snRNPs (Boulisfane et al., 2011; Girard et al., 2006; Lemm et al., 
2006). Defects in assembly of the minor spliceosome tri-snRNP have been implicated in 
altered splicing of minor introns in SMA patient lymphoblasts (Boulisfane et al., 2011). 
We have identified alterations in the dynamics of bulk splicing snRNPs using mCherry-
tagged core Sm proteins in cells expressing shRNAs targeting SMN. More detailed 
analyses revealed that these alterations affect both the major spliceosomal U1 snRNP 
(tagged with nCherry-U170K) and the minor spliceosomal U11/U12 snRNP (tagged 
with mCherry-SNRNP35). While the alterations in dynamics of mCherry-SmB-tagged 
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snRNPs were unlikely exclusively to reflect defects in the mobility of the minor 
spliceosomal snRNPs, present at 100 times lower amounts that the major snRNPs, the 
equivalent alterations seen using mCherry-U170K as a tag confirm that the major U1 
snRNP, and not just the minor U11/U12 snRNP, shows increased mobility. The 
alteration in U11/U12 snRNP dynamics was, however, greater than that in U1 snRNP 
dynamics, in broad agreement with the body of literature demonstrating more 
profound changes in the amounts of minor spliceosomal snRNPs in SMA models. Our 
data link SMN depletion to changes in the dynamic behaviour of snRNPs of the major 
and the minor spliceosomes. 
Sensitivity to SMN-depletion varies in different cell types. 
The SH-SY5Y neuroblastoma cell lines analysed in this study are viable for at least four 
days with levels of SMN, approximately 50% of wild-type, low enough to cause defects 
in snRNP mobility. However, we have so far been unable to establish SH-SY5Y cell lines 
with levels of SMN stably reduced by more than 10%. Experiments on HeLa cells (Zhang 
et al., 2008) demonstrated no loss of viability or changes in snRNP repertoire in cells 
expressing only ~20% of normal SMN levels while the reduction to ~5% required to see 
changes in splicing also resulted in cell death over 2-3 days. However, SMA mice (Zhang 
et al, 2008) survive with levels of SMN low enough to result in splicing defects and SMA 
patient fibroblasts are fully viable despite showing defects in snRNP mobility similar to 
those seen in SH-SY5Y cells with levels of SMN that are only achievable for short periods. 
Comparison of these data emphasise the different sensitivities of different cell types to 
the depletion of SMN. Since SMA preferentially affects spinal motor neurons, despite the 
need for snRNP assembly and accurate splicing in all cell types, this is highly relevant to 
the pathology of SMA. 
Increased mobility of snRNPs suggests a mechanism for inefficient spliceosome 
formation resulting from defective snRNP biogenesis. 
The mobility of factors within the nucleus occurs by anomalous diffusion, with reduced 
mobility resulting from interactions with specific binding sites. In the case of splicing 
snRNPs, the key interaction expected to retard their mobility is their incorporation into 
active spliceosomes (Rino et al., 2007). Increased mobility of splicing snRNPs in SMN-
depleted cells is, therefore, indicative of reduced binding of snRNPs within active 
spliceosomes. Pre-mRNA splicing is a highly dynamic process, with spliceosome 
assembly in vivo proposed to occur by self-organization. Splice site selection is complex 
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and determined by the balance of many positive and negative regulators (reviewed in 
Wahl et al., 2009). However, in the major spliceosome, the binding of U1 snRNP to the 5’ 
splice site is a key requirement for the formation of the spliceosomal E complex during 
the earliest stages of spliceosome assembly. The widespread defects in pre-mRNA 
splicing seen by Zhang et al appeared to preferentially involve genes with high numbers 
of introns and exons. They included not only altered selection of alternative splice sites 
but also defective splicing, suggesting a general lack of fidelity in the splicing process. 
To investigate the cause of such splicing defects, it is important to determine whether 
the changes in snRNP dynamics we see are a consequence of defective splicing resulting 
from SMN depletion by a mechanism unrelated to snRNP biogenesis or represent a 
potential link between defective snRNP biogenesis and altered splicing. 
 
Our in vivo modelling using inhibitors of different stages of pre-mRNA processing was 
designed to address a specific question: do the changes in snRNP mobility seen result 
from splicing defects or are they a potential cause for them? The results clearly 
demonstrate that the changes seen in snRNP dynamics in SMN-depleted cells can only 
be replicated by reducing the snRNP assembly pathway. LMB is known to inhibit snRNP 
maturation at the point of snRNA export into the cytoplasm by binding directly to the 
export receptor CRM1 (Kudo et al, 1997). This step closely precedes the addition of Sm 
proteins to the snRNA, which is mediated by the SMN complex and impaired in SMN-
depleted cells (Shpargel and Matera, 2005, Lemm et al, 2006). The inhibitor of 
transcriptional elongation, DRB, has traditionally been used as an indirect inhibitor of 
splicing. More recently SSA has been identified as a direct inhibitor of pre-mRNA 
splicing, believed to act via the formation of an arrested spliceosome containing U1 and 
U2 snRNPs (Roybal and Jurica, 2010) and impeding the transition from the A complex to 
the B complex. DRB, but not SSA, results in a significantly decreased half-time of 
recovery for the slower moving fraction of snRNPs, suggesting lower affinity 
interactions with spliceosomes in DRB treated cells. However, both inhibitors also 
result in alteration of speckle morphology and a significantly higher mobile fraction of 
snRNPs neither of which are seen in SMN-depleted cells. Mathematical modelling has 
previously demonstrated that decreasing the number of nucleoplasmic binding sites is 
sufficient to reproduce the effects on splicing factor kinetics and nuclear speckle 
morphology observed experimentally by inhibiting transcription using DRB, or splicing 
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using a dominant negative variant of the snRNP nuclear import adaptor snurportin1 
(Rino et al., 2007). Decreased pre-mRNA transcription (caused by DRB) or the presence 
of stable arrested spliceosomes (caused by SSA) would both be predicted to reduce the 
number of nucleoplasmic splice sites available to bind snRNPs. Inhibition of splicing 
snRNP biogenesis using LMB, however, accurately replicates the changes seen in snRNP 
dynamics following SMN depletion (Fig. 7B,C). The half time of recovery of snRNPs is 
decreased indicating lowered affinity of interaction with spliceosomes while the mobile 
fraction remains the same suggesting that the number of binding events remains 
constant. In addition to implicating the alterations in snRNP mobility as a cause, rather 
than a consequence, of inefficient splicing, this provides a direct molecular link between 
the known function of SMN in cytoplasmic stages of snRNP assembly and defects in 
splicing observed in numerous models, without needing to invoke other, as yet 
unidentified, functions for SMN. While it is still unclear whether defective splicing of key 
motor neuron transcripts is at the root of the pathology of SMA, our data provide a 
mechanistic link between reduction of SMN, a key player in the generation of the cell’s 
splicing machinery, and generalised defects in splicing. 
 
There is increasing recognition that defects in RNA metabolism underly many human 
diseases, particularly motor neuron diseases (reviewed in Cooper et al., 2009; Lemmens 
et al., 2010). The finely balanced patterns of splicing seen in mammalian cells allow for 
rapid and sensitive adjustments to protein expression during the development and 
maintenance of complex tissues and organs. However, their intricate nature is 
susceptible to perturbation, with defects in proteins involved in pre-mRNA splicing 
pathways implicated in degenerative conditions such as ALS, and cancers in addition to 
SMA. Recent research into the degenerative eye condition, retinitis pigmentosa (RP), in 
which heterozygous mutations in splicing factors associated with the U4/U6.U5 tri-
snRNP are implicated, has drawn striking parallels with SMA. Both SMA and RP appear 
to be systemic splicing diseases with cell type-specific symptoms (Linder et al., 2011; 
Tanackovic et al., 2011a; Tanackovic et al., 2011b). This implicates disrupted 
spliceosome assembly and dynamics as the cause of at least two degenerative 
conditions.  
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Materials and Methods 
Cell Culture and Cell Lines 
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal calf serum and 100 U/ml penicillin and streptomycin (Invitrogen). For 
immunofluorescence assays, cells were gown on coverslips (VWR). For live-cell 
microscopy, cells were grown on 40mm diameter coverslips (Intracel). Stable cell lines 
were established using G418 selection of SH-SY5Y cells following transfection with 
plasmids pmCherry-SmB (Clelland et al., 2009) and pmCherry-U170K (Ellis et al., 2008, 
a gift from D.Lléres and A.I.Lamond, University of Dundee) with Effectene transfection 
reagent (Qiagen) as described previously (Sleeman et al, 2001). snRNP35 (a gift from C. 
Will and R. Lührmann, Max Plank Institute for Biological Chemistry, Gottingen) was sub-
cloned into mCherry-C1 (Clontech) by Dundee Cell Products, Dundee. Stable cell lines 
were established as above. SMA patient and control fibroblasts were lines GM03813 and 
GM03814 respectively from the Coriell Cell Repository. For analysis of the effects of 
inhibitors of pre-mRNA processing, cells were incubated for 5 hours with 20µg/ml DRB 
(Sigma), 16 hours with 100ng/ml SSA (a gift from M. Yoshida, RIKEN, Japan), 3hrs, 6hrs 
or 16 hrs with 50ng/ml LMB (LC labs). 
 
RNAi Assays 
ON-TARGET plus siRNA duplexes (Dharmacon) were introduced into HeLa cells and SH-
SY5Y cells using RNAiFect (Qiagen) according to the manufacturer’s instructions. For 
shRNA expression, targeting sequences were cloned into pSuperGFP (oligoengine) 
according to the manufacturer’s instruction and the resulting plasmids transfected into 
cells. Sequences used were: Lamin A/C: GGUGGUGACGAUCUGGGCU, non-targeting 
(luciferase): UAAGGCUAUGAAGAGAUAC; PPIB: GGAAAGACUGUUCCAAAAA; SMN 01: 
CAGUGGAAAGUUGGGGACA; SMN 05: UAUAUGGGUUUCAGACAAA. 
Lamin A/C was used as a positive control in immunofluorescence assays and PPIB in 
western blot assays due to the differences in performance of antibodies to the two 
proteins in the different assays. 
 
Cell fixation, immuno-staining and microscopy 
HeLa cells grown on glass coverslips were fixed for 10 min at room temperature with 
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3.7% paraformaldehyde in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 
mM MgCl2 [pH 6.9]). Immunostaining was carried out as described previously (Sleeman 
et al., 2003). Cells were mounted in Prolong Gold medium (Invitrogen). Antibodies used 
were mouse mAbs MANSMA1 anti-SMN (Young et al., 2000) (dilution 1:10), SC-35 
(Sigma) (dilution 1:2000), Y12 anti-Sm (Abcam) (dilution 1:100), anti-TMG 
(Calbiochem, dilution 1:15) and rabbit 856 anti-U1A (Kambach and Mattaj, 1992) 
(dilution 1:500). Secondary antibodies were FITC- and TRITC-conjugated goat anti-
mouse and goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories) (dilution 
1:250). Immunostained specimens were examined and recorded using a DeltaVision 
Spectris Deconvolution microscope with an Olympus 100X, 1.35NA objective and a 
Coolsnap HQ camera (Photometrics). Optical sections separated by 200 nm were 
collected using a binning of 2x2. Images were restored using an iterative deconvolution 
algorithm using a calculated point-spread function (Volocity, Perkin Elmer). Images in 
figures 1, 2 and 3 are maximum intensity projections of z-stacks covering the entire 
depth of the cells. 
 
Quantitation of fluorescence signals 
Quantitation of the proportion of SMN signal in transfected and untransfected cells and 
nuclei was carried out using an intensity threshold on stacks of deconvolved z-sections. 
A segmentation algorithm was used to find ‘objects’ by applying a global threshold to 
each stack of z-sections. Objects were defined as sets of contiguous pixels above the 
specified threshold. To identify transfected cells, GFP signal was used to identify 
‘objects’, to identify untransfected cells, SMN signal was used. To identify nuclei, DAPI 
staining was used for ‘object’ identification and the transfected cells identified manually 
by reference to the overlaid GFP signal. In each case, the total SMN signal contained in 
each cell or nucleus was normalized to the total SMN fluorescence of the brightest cell 
or nucleus in the field of view following a correction to allow for background 
fluorescence within the sample.  
 
Preparation of cell lysates and immunoblotting 
Lysates were prepared as described previously (Sleeman et al., 2003), electrophoresed 
on a 10% SDS polyacrylamide gel (Invitrogen) and transferred to nitro-cellulose 
membranes (Hybond C+, GE Healthcare) for immunoblotting. Antibodies used were 
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rabbit anti-SMN (Santa Cruz, 1:500) and mouse anti-U-tubulin (Sigma, 1:1000). 
Secondary antibodies were HRP-conjugated anti-mouse or anti-rabbit (Pierce, 1:20000). 
Detection was carried out with ECL Plus Western Blotting Detection System (GE 
Healthcare) imaged using a Fujifilm LAS-3000 imaging system. Stripping of blots for re-
probing with anti-tubulin antibodies was carried out by incubating the blots at 50
o
C for 
30 minutes with 2% SDS, 100mM β−mercaptoethanol and 62.5 mM tris pH6.8. 
 
Live Cell Microscopy and FRAP Analyses 
Cells were grown on 40mm diameter glass coverslips and transfected with pSuper-GFP 
plamids 48hrs or 72hrs before analysis. The coverslips were transferred to an open 
chamber (Zeiss) within an environmental incubator (Solent Scientific) on an Olympus 
DeltaVision RT microscope (Applied Precision) with a Quantifiable Laser Module 
including a 20mW 532nm laser and maintained at 37
o
C with 5% CO
2
. Transfected cells 
expressing GFP were identified using FITC filters. Nuclear speckles within selected cells 
were bleached using a 1s 532nm pulse at 100% laser power focused to a diffraction-
limited spot of approximately 0.5 µm. The duration of bleaching achieved a reduction of 
fluorescence in the region of interest of approximately 60%. A single z-section of each 
cell was imaged using a texas red filter at 3 timepoints before the laser pulse and an 
adaptive time course of 32 timepoints after the laser pulse. For single-phase recovery 
analyses, images were normalized for mean intensity and models generated using the 
method of Axelrod (Axelrod et al., 1976) as implemented within SoftWoRx software. For 
comparison of one-phase and two-phase recovery, the intensities of the region of 
interest, corrected for photo-bleaching, were normalized against the initial pre-bleach 
fluorescence and plotted against time. One- and two-phase exponential association 
curves were fitted to each data set and an extra sum-of-squares F test performed to 
determine which model gave the better fit (GraphPad Prism). In all cases, the two-phase 
curve gave the better fit (P<0.0001). Equations used were as follows: 
 
Y=Ymax1 x (1-exp(-K1 x X)) + Ymax2 x (1-exp(-K2 x X)) 
  
Y=Ymax x (1-exp(-K x X)) 
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Half-times of recovery and mobile fractions were compared using a one-way ANOVA 
test with Tukey-Kramer post-test. 
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Figures and Legends 
 
Figure1 
SMN can be effectively reduced by RNAi in HeLa and SH-SY5Y cells 
A) Immunofluorescent detection of SMN (green, left hand panels) in HeLa cells 
transiently transfected with siRNA duplexes shows lowered staining and loss of nuclear 
gems (arrows in control panels i and ii) in cells transfected with two independent 
duplexes targeting SMN (panels iii and iv). Right hand panels (DAPI) show the positions 
of the nuclei. Bar=10µm. B). The number of nuclear gems per cell is dramatically 
reduced by siRNA duplexes in HeLa cells. Data represented as mean+/- SEM, n=80 cells 
per duplex pooled from two independent experiments. C) Western blot analysis of SH-
SY5Y cells transfected with siRNA duplexes targeting SMN for 24 or 48hrs show a 
strong reduction in SMN protein compared to negative control non-targeting duplexes 
and positive control duplexes targeting PPIB. Anti-tubulin confirms even loading of 
samples. Lanes containing additional positive controls have been cut from the blot. D) 
Quantitation of western blots, normalized to tubulin signal, reveals a reduction to 48% 
of normal after 24 hours (mean of two independent experiments, data represented as 
mean+/- SEM) and to 32% of normal after 48hrs. 
 
Figure 2 
SMN reduction can be achieved using expression of shRNAs 
Immunodetection of SMN (left hand panels and red signal in right hand panels) in cells 
transfected with plasmids to express shRNAs targeting SMN (A, B and C) or a positive 
control targeting PPIB (D). The inclusion of a GFP expression cassette on the plasmid 
allows unequivocal identification of transfected cells (green signal in right hand panel 
and arrows). Expression of shRNAs targeting SMN for 24hrs does not result in an 
appreciable decrease in SMN protein (A, arrowhead shows an SMN-positive nuclear 
gem), while 48hrs or 72hrs of expression results in loss of SMN from the nucleus and 
cytoplasm (B and C). Cells expressing shRNAs to PPIB show strong SMN expression at 
all three time points (D and other data not shown). Bar=10µm. E) Quantitation of anti-
SMN fluorescence signal in transfected and untransfected cells and nuclei demonstrate 
reduction of SMN to 46% of control in whole cells and to 56% of control in nuclei. 
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Measurements were made from deconvolved z-stacks of a total of 40 cells, data 
represented as mean+/- SEM. 
 
Figure 3 
Reduction of SMN does not disrupt the structure of splicing speckles. 
SMN-depleted SH-SY5Y cells (identified by GFP expression, green in lower panels) show 
normal speckled distribution of the SR splicing factor, SC-35 (A), the core snRNP Sm 
proteins (B), the U1 snRNP-specific protein U1A (C) and snRNAs detected using 
antibodies to their tri-methyl guanosine cap structure (D). Cytoplasmic accumulations 
of snRNAs are also readily detected in both SMN-depleted and control cells 
(arrowheads in D). Bar=10µm. 
 
Figure 4 
SMN depletion increases the mobility of mCherry-SmB-tagged splicing snRNPs, 
preferentially affecting a slow-moving fraction. 
A) Stably expressed mCherry-SmB (i, red in iii) co-localises with endogenous Sm 
proteins (ii, green in iii) in SH-SY5Y cells. The signal is predominantly within the 
nucleus, identified by DAPI staining (blue) in iii) with clear accumulation seen in 
splicing speckles (arrows in C). Bar=10µm. B) Representative images of a FRAP 
experiment in cell line mCherrySmBSHY12. The magenta circle marks the bleach region 
with the pseudocolour spectrum showing the highest intensity pixels in red and the 
lowest in blue. Images show the cell before bleaching, immediately after bleaching and 
at the end of the recovery time-course when partial recovery of fluorescence has 
occurred. Bar=10µm. C) Recovery curves for cells transfected with control plasmids 
(black) or a plasmid expressing shRNA sequence SMN01 to deplete SMN (red). Mean +/- 
SEM from 30 FRAP time-courses for each condition, pooled from two independent 
experiments. D) The observed half-time of recovery of mCherrySmB to speckles is 
significantly reduced in cells with depleted SMN compared to those transfected with 
negative control plasmids (mCherrySmBSHY12 48 hours (n=38, P<0.001) and 
mCherrySmBSHY03 48 hours (n=27, P<0.01)) or positive control plasmids targeting 
PPIB (mCherrySmBSHY12 72 hours (n=29, P<0.001)). Although the half-life 
mCherrySmB in control cells of line mCherrySmBSHY03 is longer than that seen in line 
mCherrySmBSHY12, a similar decrease is seen following SMN reduction. The mobile 
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fraction of mCherrySmB is unaltered by SMN depletion in either cell line. All data 
represented as mean+/- SEM. E) Comparison of one-phase (dotted line) and two-phase 
(solid line) recovery models of FRAP data sets reveal a significantly better fit using a 
two-phase model (P<0.0001). Example data sets shown are of line mCherrySmBSHY12 
transfected for 48hrs, also included in figure 4C. F) Detailed analysis of the recovery 
kinetics from mCherrySmBSHY12 reveals that the decrease in the overall half-time of 
recovery reflects increased mobility (decrease in t1/2) of a slower moving fraction of 
mCherrySmB, with a faster moving fraction unchanged by SMN-depletion. Data 
represented as mean +/- SEM, n=38. 
 
Figure 5 
SMN depletion increases the mobility of the major spliceosomal U1 snRNP and the minor 
spliceosomal U11/12 snRNP. 
A) Representative images of a FRAP experiment in cell line mCherryU170KSHY05. The 
magenta circle marks the bleach region with the pseudocolour spectrum showing the 
highest intensity pixels in red and the lowest in blue. Images show the cell before 
bleaching, immediately after bleaching and at the end of the recovery time-course. 
Bar=10µm. B) Analysis of the FRAP kinetics of mCherry-U170K reveals an increase in 
the mobility of the slower-moving fraction of signal. Data represented as mean +/- SEM, 
n=82, pooled data from two independent experiments. C) Deconvolved images of 
mCherry-SNRNP35 (red) shows nuclear localization with a slight accumulation in 
nuclear speckles (arrows) detected with anti-Sm antbodies (green). D) Representative 
images of a FRAP experiment in cell line mCherrySNRNP35SHY02. Bar=10µm. E) 
Analysis of the FRAP kinetics of mCherry-SNRNP35 reveals an increase in the mobility 
of the slower-moving fraction of signal. Data represented as mean +/- SEM, n=37, 
pooled data from two independent experiments. 
 
 
Figure 6 
Fibroblasts from an SMA patient show an increase in snRNP mobility in the absence of 
disruption of splicing speckles. 
Fibroblasts from an SMA patient (lower panels) show normal localisation of the SR 
splicing factor, SC-35 (A) and the core snRNP Sm proteins (B) to speckles (arrows) 
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when compared to fibroblasts from the patient’s unaffected mother (upper panels). 
Bar=10µm. C) Analysis of the FRAP kinetics of mCherry-U170K transiently transfected 
into patient and control fibroblasts reveals an increase in the mobility of the slower-
moving fraction of signal. Data represented as mean +/- SEM, n=58, pooled data from 
two independent experiments. 
 
Figure 7 
Inhibition of the snRNP processing pathway with leptomycin B accurately replicates the 
effects of SMN depletion 
A) Representative images of live cells expressing mCherry-SmB treated with inhibitors 
of different stages of pre-mRNA processing. Inhibition of transcription (DRB) or splicing 
(SSA) results in abnormal splicing speckle morphology (arrows). Inhibition of snRNP 
assembly (LMB) has no detectable effect on the morphology of splicing speckles 
compared to the no drug control. B) FRAP recovery curves show altered dynamics in 
cells treated with DRB (blue), SSA (green) and LMB (red). The alteration in the curve 
obtained with LMB closely resembles that caused by SMN depletion (figure 4). Data 
represented as mean +/- SEM. C) Inhibition of transcription (DRB, blue) causes a 
significant decrease in the t1/2 of the slower moving fraction of snRNPs, accompanied 
by an increase in the mobile fraction of the faster component (n=69). Inhibition of pre-
mRNA splicing (SSA, green) does not show a significant alteration in either t1/2 but 
results in a significant increase in the mobile fraction of the faster signal (n=70). 
Inhibition of snRNP processing (LMB, red) shows a similar decrease in the slower t1/2 
as is seen in SMN-depleted cells, with unaltered mobile fractions (n=66). 
 
Figure 8 
Summary of the effects of inhibitors of different stages of pre-mRNA production on intra-
nuclear snRNP mobility and splicing speckle structure 
In control cells, snRNPs exchange continually between speckles (red) and active self-
organized spliceosomes, denoted by the black arrow, leading to efficient splicing. The 
transcriptional inhibitor, DRB, reduces the number of splice sites present, resulting in a 
larger mobile fraction of snRNPs, faster return of snRNPs to speckles and abnormal 
speckle morphology. By arresting splicing with a stabilized A complex (pink star), SSA 
reduces the number of splice sites available for snRNP binding, again resulting in a 
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larger mobile fraction of snRNPs and abnormal speckle morphology. Reduction of the 
efficiency of snRNP assembly by LMB or reduction of SMN increases the rate of return of 
snRNPs to speckles, making them less available for spliceosome formation without 
affecting speckle morphology. 
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